Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1967847 | 0.94 | HCRTR1 (0.43) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL1969058 | 0.90 | HCRTR1 (0.45) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL2405009 | 0.90 | HCRTR1 (0.44) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL2407515 | 0.90 | HCRTR1 (0.42) | HCRTR1HCRTR2 | |
| SCHEMBL2404671 | 0.89 | HCRTR1 (0.43) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL1970670 | 0.89 | HCRTR1 (0.44) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL1971731 | 0.88 | HCRTR1 (0.46) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL1965921 | 0.88 | HCRTR1 (0.53) | HCRTR1HCRTR2 | |
| SCHEMBL1965407 | 0.88 | HCRTR1 (0.39) | HCRTR1HCRTR2PDE4B | |
| SCHEMBL1969724 | 0.86 | HCRTR1 (0.42) | HCRTR1HCRTR2PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885PDE4B 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.